GlassScriptPhysician profile
Jeremiah Ojeaburu
NPI 1306810023
$1,035.68
in general payments reported to CMS, 2019-2025
13 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.13 · 2022: $13.64 · 2024: $147 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $335.81 | 2025 | Voquezna |
| Abbvie INC. | $249.03 | 2022-2025 | |
| Janssen Biotech, INC. | $136.77 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $85.36 | 2024-2025 | Entyvio |
| Ardelyx, INC. | $42.93 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $36.86 | 2025 | Rezdiffra |
| Novo Nordisk INC | $36.66 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $35.22 | 2025 | Dupixent |
| Lilly USA, LLC | $26.43 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $21.06 | 2025 | |
| Apollo Endosurgery US INC | $15.13 | 2021 | |
| Pfizer INC. | $14.42 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,464.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Ojeaburu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.